Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor added to mechanical thrombectomy for perfusion-selected acute ischemic stroke
2024-516163-88-00Phase 4Completed
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Aug 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cangrelor in ischemic stroke (2 arms), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Favorable functional outcome at 3 months. Started Aug 2024; status: completed.
02
Drugs
cangrelor
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-516163-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516163-88-00.